Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D08QHX
|
||||
| Former ID |
DCL001223
|
||||
| Drug Name |
PRX00933
|
||||
| Indication | Obesity; Diabetes [ICD9: 250, 278; ICD10:E08-E13, E66] | Phase 2 | [1] | ||
| Company |
Proximagen Group plc
|
||||
| Target and Pathway | |||||
| Target(s) | 5-hydroxytryptamine 2C receptor | Target Info | Agonist | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Serotonergic synapse | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| PANTHER Pathway | 5HT2 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Serotonin Receptor 2 and ELK-SRF/GATA4 signaling | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2011 Pipeline of Proximagen Group plc. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.